Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (about 85% of lung cancers) and it usually grows and spreads more slowly than small cell lung cancer. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer. Non-small cell lung cancer is a major type of lung cancer, accounting about 80% to 90% of the total lung cancers, with one of the highest mortality rates. Treatment of NSCLC depends on the stage of cancer, type of NSCLC, type of mutation gene such as epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) gene, and patient’s general health.
The global non-small cell lung cancer therapeutics market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug classes (angiogenesis inhibitors – Avastin, Cyramza; epidermal growth factor receptor blockers – Tarceva, Gilotrif or GIOTRIF, Iressa; Folate antimetabolites – Alimta; kinase inhibitors – Xalkori, Zykadia; microtubule stabilizers – Abraxane, Docetaxel; and PD-1/ PD-L1 inhibitors – Opdivo, Keytruda), clinical pipeline analysis of phase 1, 2 and 3 drugs (Avelumab, MPDL3280A, MEDI4736, Abemaciclib, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
The global non-small cell lung cancer therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global non-small cell lung cancer therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global non-small cell lung cancer therapeutics market and included in this report are AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech (Roche), Novartis AG, Pfizer, Inc., and Sun Pharmaceutical Industries Ltd.